GILD Gilead Sciences
Long-acting HIV extends a cash machine's runway; value hinges on M&A discipline, not the IPR&D-distorted GAAP loss.
The story
Gilead is a mature, cash-rich HIV franchise (Biktarvy, plus long-acting lenacapavir for PrEP and treatment) that funds a mixed oncology and liver portfolio and frequent acquisitions. The HIV moat comes from switching costs and a long-acting pipeline that pushes patent risk into the late 2030s. Growth is mid-single-digit, and the company is in the mature-but-durable stage of its life cycle. The negative TTM GAAP margin comes from acquired IPR&D charges, not deteriorating core economics.
Growth and terminal assumptions are unchanged; TTM revenue up 5.3% confirms about 6%. I made three material moves. Sales-to-capital rises from 0.62 to 0.85 because lenacapavir growth is organic and the 0.65 historical figure is inflated by acquisition goodwill. Horizon goes from 8 to 10 years because long-acting HIV extends franchise durability. Failure probability drops to 0.02 given $31B of revenue and investment-grade cash flows. The prior value of $71 against a $151 to $168 price implied a gap of over 100% that the facts no longer support.
Value drivers
| Revenue growth (Y1) | 6.0% |
| Terminal growth | 3.5% |
| Forecast horizon | 10y |
| Target operating margin | 37.0% |
| Years to target margin | 3 |
| Sales-to-capital | 0.85 |
| Beta | 0.90 |
| Failure probability | 2.0% |
| Cost of capital (WACC) | 8.8% |
| Terminal WACC | 9.2% |
Valuation bridge
| PV of explicit FCFF | 58.27B |
| PV of terminal value | 76.83B |
| Equity value | 115.45B |
| ÷ shares → per share | $93.08 |
Projected free cash flow to the firm
| Yr | Revenue | Growth | Margin | NOPAT | Reinvest | FCFF | PV |
|---|---|---|---|---|---|---|---|
| 1 | 32.85B | 6.0% | 9.1% | 2.58B | 2.19B | 397.55M | 365.44M |
| 2 | 34.73B | 5.7% | 23.0% | 6.95B | 2.21B | 4.74B | 4.00B |
| 3 | 36.62B | 5.4% | 37.0% | 11.77B | 2.22B | 9.55B | 7.41B |
| 4 | 38.51B | 5.2% | 37.0% | 12.38B | 2.23B | 10.15B | 7.25B |
| 5 | 40.39B | 4.9% | 37.0% | 12.98B | 2.21B | 10.77B | 7.07B |
| 6 | 42.25B | 4.6% | 37.0% | 13.58B | 2.19B | 11.39B | 6.87B |
| 7 | 44.08B | 4.3% | 37.0% | 14.17B | 2.15B | 12.02B | 6.66B |
| 8 | 45.87B | 4.1% | 37.0% | 14.74B | 2.10B | 12.64B | 6.44B |
| 9 | 47.61B | 3.8% | 37.0% | 15.30B | 2.04B | 13.26B | 6.21B |
| 10 | 49.27B | 3.5% | 37.0% | 15.84B | 1.96B | 13.88B | 5.98B |
Key risks
- Large IPR&D and M&A charges keep destroying value (TTM net loss of $3.9B)
- IRA price negotiation and Medicare Part D redesign compress HIV net pricing
- Oncology (Trodelvy, cell therapy) underdelivers, leaving the company dependent on HIV
Catalysts
- Yeztugo (lenacapavir PrEP) uptake and payer coverage ramp
- Once-weekly and twice-yearly HIV treatment combination readouts